Clinical Research Trials

Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.

Y-HEP Health Center | Jonathan Lax Health Center


The following clinical trials are ongoing at the Lax Center and currently enrolling patients:

 

There are currently no trials enrolling patients at the Lax Center. Please check the Research Department bulletin board on the 5th floor at 1233 Locust St. for trials enrolling at other local health centers.


The following clinical trials are ongoing at the Lax Center but are NOT enrolling new patients:

Beyond Antiretroviral Treatment: Reducing Proviral HIV DNA with Interferon-α Immunotherapy (BEAT-HIV): A randomized, multi-site, open-label study to assess the effectiveness of Peg-IFN-α2b in decreasing the levels of cell-associated, integrated viral DNA in HIV chronic infection

Open-label study to evaluate switching from a regimen of two NRTIs plus a third agent to a fixed dose combination of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed, HIV-1 infected, African American participants

Trial number: GS-US-380-4580

Description: A phase 3b, open-label study to evaluate switching from a regimen of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus a third agent to a fixed dose combination (FDC) of bectegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed, HIV-1 infected, African American participants.

Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis (PrEP)

Trial Number: GS-US-412-2055

Description: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women who have Sex with Men and are at Risk of HIV-1 Infection

Double-Blind Study to Evaluate Safety and Efficacy of GS-9883 versus Triumeq in HIV+, Treatment-Naïve Adults

Trial Number: GS-US-380-1489

Description: A Phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 infected, antiretroviral treatment-naïve adults

Randomized, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressed [TANGO]

Trial Number: 204862

Description: A phase 3, randomized study aiming to determine the efficacy, safety and tolerability of two approved medicines, dolutegravir (DTG) plus lamivudine (3TC) taken together, compared with subjects taking their current tenofovir alafenamide (TAF)-based regimen (TBR) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed.

Switch Study to Evaluate D/C/F/TAF, Once-Daily versus Staying on a Boosted Protease Inhibitor Regimen

Trial Number: TMC114IFD3013
Description: A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily, single-tablet regimen versus continuing the current regimen consisting of a boodted protease inhibitor (bPI) combined with emtricitabine/tenofovir disproxil fumerate (FTC/TDF) in virologically-suppressed, human immunodeficiency virus, type-1 (HIV-1) infected subjects

The Immunopathogenisis of HIV

Description: Sponsored by The Wistar Institute


The following clinical trials are ongoing at the YHEP Youth Health Center and currently enrolling patients:

A Demonstration of PrEP Counseling and Administration in Two Family Planning Settings
Note: This study is enrolling cis and transgender women.


For more information on any of the clinical trials listed, please contact the Research Department at 215-525-8695.

Program Information

  • Phone: 215-525-8695

Spotlight On

Karam Mounzer, MD

Dr. Mounzer identified two major gaps in the care of patients with HIV/hepatitis C (HCV) co-infection, and the complexity of multidrug-resistant HIV treatment. He is involved with many clinical trials focusing on drug development and better understanding of HIV immunopathogenesis with the Wistar Institute. He is involved in teaching and mentoring.

Learn More about Spotlight On
Dr. Karam Mounzer

Dr. Mario Cruz

Dr. Mario CruzDr. Cruz is a board certified pediatrician who joins Philadelphia FIGHT as the Medical Director for our Pediatrics and Adolescent Health Center. He completed his undergraduate training in Biology and Psychology from Union College, his medical school training at Albany Medical College, his residency training at St. Christopher’s Hospital for Children, and his Chief Residency at the Albert Einstein Medical Center.


Translate »